Empagliflozin Treatment is Associated with Improved Beta Cell Function in T2DM.
| Author | |
|---|---|
| Abstract |
:
To examine whether lowering the plasma glucose concentration with empagliflozin (SGLT2 inhibitor) improves beta cell function in T2DM. |
| Year of Publication |
:
2018
|
| Journal |
:
The Journal of clinical endocrinology and metabolism
|
| Date Published |
:
2018
|
| ISSN Number |
:
0021-972X
|
| URL |
:
https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2017-01838
|
| DOI |
:
10.1210/jc.2017-01838
|
| Short Title |
:
J Clin Endocrinol Metab
|
| Download citation |
